CEO left million-dollar company in favor of clinical-stage biotech firm
The CEO in Danish Specific Pharma has stepped down from her position to join a promising biotech firm and potential Leo Pharma-rival.
Danish biotech firm MC2 Therapeutics is approaching a potential breakthrough after announcing positive data in phase II- and phase III clinical trials with candidates against dry eyes and plaque psoriasis. The company expects to launch the psoriasis candidate in the US and then Europe in 2020/2021.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Danish company takes candidate to phase III
For abonnenter
.jpg&w=384&q=75)
